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Early closure remains a significant problem after
infrainguinal bypass grafting; it occurs in 3% to 15%
of cases.1-6 In some instances technical error or poor
runoff is found to be responsible.1,2 However, in a
number of cases neither of these factors appears to
account for graft occlusion. Increased platelet reac-
tivity to collagen and an increase in factor VIII activ-
ity after femorodistal bypass grafting have been
described.7 It has been hypothesized that this
increase in thrombogenicity has been responsible for
the early failure of a number of bypass grafts. 
Dextran 40 is composed of long-chain carbohy-
drate polymers with a mean molecular weight of
40,000. In vivo it has been shown to be an effective
plasma expander that lowers blood viscosity and
increases peripheral blood flow.8,9 In addition, it has
been shown to inhibit platelet adhesion and to
specifically interfere with the interaction of factor
VIII, platelets, and endothelial cells.10,11 Several
studies have suggested that the administration of
dextran 40 increased the early patency of infrain-
guinal bypass grafts.12,13 As a result, many surgeons
began to use dextran as a routine adjunct to lower
extremity arterial reconstruction. With the hope of
better delineating its role in lower extremity revas-
cularization, we began a prospective and random-
ized study to determine whether dextran 40
improved the early patency of autogenous infrain-
guinal bypass grafts.
METHODS
Between July 1992 and June 1996 we performed
292 autogenous infrainguinal bypass grafts. After
informed consent had been obtained, 244 patients
were entered into and completed the study protocol.
These patients underwent a total of 273 operations.
After the drawing of presealed opaque envelopes
each patient was randomized to either the dextran or
the non-dextran group. Nineteen additional patients
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Purpose: We determined whether the administration of dextran 40 would increase the
early (30-day) patency of autogenous infrainguinal bypass grafts. 
Methods: During a 4-year period, 244 patients undergoing 273 autogenous infrainguinal
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randomized into two groups; one of the groups received a 72-hour infusion of dextran
40 after surgery, and the other did not. Comparisons were made between those patients
who did and did not receive dextran 40 with respect to risks factors, demographics, and
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bypass graft (popliteal vs tibial). Among those patients receiving dextran, there were
eight early occlusions (6.4%) and four deaths (3.2%); 89.7% of the patients were alive
with patent grafts 30 days after surgery. In the group not receiving dextran, there were
10 early occlusions (6.8%) and 3 deaths (2%); 90.5% of the patients were alive with
patent grafts 30 days after surgery. There was no significant difference between the two
groups with respect to rate of early occlusion (p = 1.00), death (p = 0.71), or 30-day
patency (p = 0.84).
Conclusions: The administration of dextran 40 does not increase the early patency of
autogenous infrainguinal bypass grafts. Its routine use during these procedures cannot
be recommended. (J Vasc Surg 1998;28:23-7.)
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were excluded from the study; these included two
patients who refused randomization, four patients
who had their dextran discontinued because of com-
plications, six patients with recent bouts of conges-
tive heart failure, and seven patients with creatinine
levels above 2 mg/dL not yet requiring dialysis. 
Patient demographics, preoperative risk factors,
and indication for surgery were noted in all cases.
Graft patency at 30 days or early closure was con-
firmed by duplex scan. Initial graft occlusion was
used as the endpoint of the study, and secondary
graft patency was not evaluated.
Infrainguinal bypass grafts were performed with
patients under regional anesthesia unless the har-
vesting of arm veins was required; for these cases,
general anesthesia was used. All grafts were per-
formed in reversed fashion. Dextran 40 infusions
were begun after induction of anesthesia. The first
bottle of dextran (500 mL) was administered over 5
hours as a loading dose. A constant infusion of dex-
tran 40 was then begun immediately, and the patient
received 500 mL during each 24-hour period for a
total of 72 hours. All patients were anticoagulated
with 5000 units of sodium heparin before arterial
clamping. Protamine sulfate was not used to reverse
the effect of heparin. Patients on chronic oral anti-
coagulants or antiplatelet agents had their medica-
tions discontinued 1 week before surgery and
restarted 1 week after surgery.
Randomization was performed by the lottery
method. Five hundred opaque envelopes were pre-
pared before the study was undertaken. One half of
the envelopes contained dextran cards; the other half
contained non-dextran cards. The envelopes were
then placed in a bin and shuffled. For each patient eli-
gible for inclusion in the randomization process, a sin-
gle card was drawn before surgery. Preparation and
selection of the envelopes was performed by office
personnel not involved in the research protocol. 
Randomization was performed before every
operation, and for the purposes of statistical analysis
each procedure was considered separately.
Comparisons of demographic data, risk factors, indi-
cation for surgery, and rates of early graft occlusion
(30 days) were made between the two groups. c2
and Fisher exact tests were used to analyze the cate-
gorical factors. The Student t test was performed to
test for differences in the mean level of specific fac-
tors. Statistical significance was assumed at a p level
less than 0.05. Sample sizes were selected to enable
a difference of 30% in the rate of early graft occlu-
sion between the two groups to be detected at a
power of 80%. Differences less than this were con-
sidered to be clinically insignificant. 
RESULTS
One hundred twenty-six procedures in the trial
were accompanied by the use of dextran; 147 proce-
dures were not. Of the patients included in the study,
63% were male and 37% were female; their ages
ranged from 43 to 94 years, with a mean of 72.2
years. Forty-five percent of the patients had diabetes,
42% had symptomatic heart disease, and 41% were
under treatment for hypertension. Forty-five percent
of the patients smoked 20 or more cigarettes per day.
There was no significant difference in demographic
data or risk factors between patients who did and
patients who did not receive dextran (Table I).
Indications for surgery included claudication in
26% of patients, nonhealing ulcer in 26%, ischemic
rest pain in 25%, and gangrene in 23%. Fifty-three
percent of the grafts were to the popliteal artery
(38% above knee and 62% below knee), and 47% of
the grafts were to the infrapopliteal vessels. Ninety-
one percent of the grafts were performed with
greater saphenous vein, 8% with arm vein, and 1%
with lesser saphenous vein. There was no significant
difference in indication for surgery, distal target ves-
sel, or type of conduit between patients who did and
patients who did not receive dextran (Table II).
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Table I. Demographics and risk factors
Dextran Non-dextran
Variable (n = 126) (n = 147) p value
Mean age (yr) 72.2 ± 10.1 72.1 ± 9.8 0.87
Gender Male, 72 (57%) Male, 100 (68%) 0.08
Female, 54 (43%) Female, 47 (32%)
Smoking 50 (40%) 73 (50%) 0.11
Heart Disease 46 (37%) 70 (48%) 0.07
Coagulopathy 4 (3.2%) 4 (2.7%) 1.00
Diabetes 54 (43%) 68 (46%) 0.63
COPD 7 (5.6%) 6 (4.1%) 0.58
Hypertension 46 (37%) 68 (46%) 0.11
Hyperlipidemia 7 (5.6%) 8 (5.4%) 1.00
Table II. Type of operation and conduit
No. patients (%)
Dextran Non-dextran
Variable (n = 126) (n = 147) p value
Fem-Pop 71 (56) 73 (50) 0.28
Fem-Tib 29 (23) 44 (30) 0.22
Pop-Tib 26 (21) 30 (20) 1.00
Saphenous vein 119 (94.4) 132 (89.7) 0.19
Arm vein 6 (4.8) 13 (8.9) 0.24
Lesser saphenous 1 (0.8) 2 (1.4) 1.00
Five patients had complications that were felt to
be secondary to dextran administration 48 to 96
hours after surgery. Four patients (three with heart
failure and one with renal failure) had their dextran
discontinued before infusion was complete, and they
were excluded from the study. None of these
patients had early graft occlusion, but one died with-
in 30 days of surgery. Another patient experienced
an elevation of her creatinine level to 5 mg/dL with
oliguria soon after finishing her course of dextran
therapy. Her renal function returned to normal in 12
days.
Overall, 18 patients (6.6%) had closure of their
grafts within 30 days of operation. Eight patients to
whom dextran was administered (6.4%) and 10
patients to whom it was not (6.8%) experienced early
graft occlusion. Seven patients (2.6%) died within 30
days of surgery; four of these patients had received
dextran and three had not. There was no significant
difference between the two treatment groups with
respect to rate of early graft occlusion (p = 1.00) or
rate of perioperative death (p = 0.71). One patient
who received dextran and two patients who did not
underwent revision of hemodynamically failing but
patent grafts within 30 days of operation. One
patient in each group required graft removal for
infection. Ninety percent of patients were alive with
functioning grafts 30 days after surgery (Tables III
and IV).
DISCUSSION
The immediate perioperative period remains a
precarious time for infrainguinal bypass grafts.
Elevated levels of factor VIII, increased activation of
platelets, and decreased levels of antithrombin III
create a hypercoagulable state during the first days
after graft implantation, and it is during this time
that a number of unexplained graft failures occur.7 It
has been postulated that some of these grafts would
achieve long term patency if early occlusion could be
avoided. Surgeons have been reluctant to use full
anticoagulation with heparin or warfarin in the
immediate perioperative period for fear of bleeding
complications, and traditional antiplatelet therapy
has not been convincingly shown to decrease early
graft thrombosis. This has led to the search for a
drug that would selectively neutralize the hyperco-
agulable state found in the early perioperative period
without creating a prohibitive risk of hemorrhage.
Dextran appeared to be an attractive alternative
to heparin anticoagulation and antiplatelet agents.
Its ability to inhibit factor VIII activity, increase clot
lysability, and decrease the aggregation of platelets in
response to collagen seemed ideal in combating the
postoperative hypercoagulable state.10,11,13 Dextran
had proved its efficacy in the prevention of deep vein
thrombosis and had been successful in preventing
thrombosis of small vessels in experimental mod-
els.8,9 Several clinical studies suggested that dextran
was effective in preventing early thrombosis of
infrainguinal bypass grafts, particularly those to the
infrapopliteal vessels and those in which autologous
vein had not been used.12,13 This evidence led many
surgeons to use dextran as an adjunct to almost all
infrainguinal arterial reconstructions, even though
its efficacy in improving the patency of autogenous
bypass grafts had not been conclusively proved.
Unfortunately, dextran is not without its unto-
ward effects. Acute renal failure, congestive heart
failure, thrombocytopenia, and anaphylaxis after its
use have all been reported, and as with all pharma-
cologic agents the risks and benefits of its adminis-
tration must be carefully weighed.14-16
The dosage and method of administration of
dextran have not been well standardized. Various
investigators have given patients 500 to 1000 mL
during each 24-hour period for times ranging from
1 to 5 days. Dextran has been given either by inter-
mittent rapid bolus or by continuous infusion. Early
in our experience, we attempted to follow the inter-
mittent rapid infusion protocol described by
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Table III. Indication for surgery
No. patients (%)
Dextran Non-dextran
Variable (n = 126) (n = 147) p value
Claudication 33 (26) 37 (25) 0.89
Rest pain 28 (23) 40 (28) 0.40
Ulcer 33 (26) 37 (25) 0.89
Gangrene 32 (25) 33 (22) 0.57
Table IV. Rates of early graft failure
No. patients (%)
Dextran Non-dextran
Variable (n = 126) (n = 147) p value
Early 8 (6.4) 10 (6.8) 1.00
occlusion*
Early occlusion 4 (7.3) 6 (8.1) 1.00
of tibial grafts
Grafts patent 113 (89.7) 133 (90.5) 0.84
at 30 days
Death 4 (3.2) 3 (2.0) 0.71
*Occlusion by gender: female, 8 (7.9%) ; male, 10 (5.8%); p = 1.00.
Dr. Robert B. Rutherford (Silverthorne, Colo.). In a
single institution prospective randomized trial, Drs. Katz
and Kohl were unable to demonstrate a protective effect
of Dextran 40 on the patency of autogenous infrainguinal
bypass grafts. Over 90% of the grafts were greater saphe-
nous vein grafts, and just over 50% were to the popliteal
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Rutherford13; this led to an unacceptably high inci-
dence of congestive heart failure in our patient pop-
ulation. We then adopted our current method of
administering an initial bolus of dextran during the
induction of anesthesia followed by the continuous
administration of 500 mL every 24 hours. This
method has the advantage of rapidly achieving a
high plasma drug concentration and maintaining
this level throughout the treatment course. Even
with this approach several episodes of heart failure
appeared to be precipitated by the dextran. The
choice of a 72-hour period of therapy reflects the
fact that most of our patients were discharged on
the third postoperative day; we could not justify
prolonging the hospital stay solely for the sake of
our research protocol.
In contrast to other studies, our trial focused
exclusively on patients undergoing autogenous
bypass grafting. The rate of graft closure and the
makeup of the patient population in this series are
comparable to those reported by others.1-6 In addi-
tion, the two treatment groups were closely matched
for risk factors, patient demographics, and type of
operation performed, and the sample sizes were
large enough to have made possible the detection of
a relatively small difference in early occlusion rate
(30%) between the two groups. Still we were unable
to observe any difference in early graft failure rate
between patients who did and patients who did not
receive dextran. It is probable that any observed
benefit of dextran therapy is conferred only on
patients who receive prosthetic bypass grafts.
In summary, we conclude that dextran does not
improve the early patency of autogenous infrain-
guinal bypass grafts. Although they are rare, serious
and potentially fatal side effects of its administration
do occur. There may be subsets of patients who
might benefit from dextran administration (those
with veins of poor quality, those with poor outflow,
and those undergoing prosthetic bypass grafting),
but its routine use as an adjunct to lower extremity
revascularization performed with autologous vein
cannot be recommended.
Statistical analysis was provided by Stanley Azen, PhD,
of the University of Southern California, School of
Medicine, Division of Biometry.
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DISCUSSION
artery. Runoff was not characterized. In view of this, I am
not surprised at the outcome and agree with their conclu-
sions that Dextran 40 should not be routinely used for
infrainguinal bypass grafts with saphenous vein grafts.
In fact, we came to the same conclusion in a multicen-
ter prospective randomized trial reported in the Journal of
Vascular Surgery over 13 years ago. However, we deliber-
ately studied only “difficult” distal bypass grafts because we
wanted enough cases at risk for early thrombosis to show
an effect. Therefore, we entered vein grafts only if they had
poor runoff or terminated in crural arteries. Even so, the
thrombosis rate for both control and Dextran 40 vein
grafts was identical and only 2.6%. However, in the remain-
ing cases, consisting of polytetrafluoroethylene or umbilical
vein grafts, or in those requiring adjunctive procedures,
such as endarterectomy, the 1-week thrombosis rate for
controls was 36% compared with only 12% for those receiv-
ing Dextran 40. In our follow-up of this trial, the patency
rate difference in favor of those with polytetrafluoroethyl-
ene or umbilical vein grafts receiving Dextran 40 was sta-
tistically significant to 32 months.
Admittedly, a significant amount of the initial benefit of
Dextran 40 was lost between 1 week and 1 month because,
presumably in the face of technical imperfections or poor
runoff flow, it only delayed inevitable thrombosis. Yet,
when we closed the trial at 195 cases, rather than the 156
we reported, the advantage for Dextran 40 was still statis-
tically significant at 1 month, without graft stratification.
Therefore, I still feel Dextran 40 is beneficial in any
scenario in which the risk of early thrombosis is high. Our
control thrombosis rate was close to 21%, three times
higher than in the present trial, which is why I think we
were able to show some benefit.
Finally, there is concern about the risk of Dextran 40.
With the exception of infusion protocol violations, this was
not observed in our trial because patients with a history of
congestive heart failure and renal disease were specifically
excluded. However, in later practice, I adopted the same
protocol as used in this trial to avoid the dangers of bolus
administration, although I still administer it for 4 days.
I enjoyed reading the manuscript and feel we should
thank the authors for demonstrating that the routine use of
Dextran 40 in infrainguinal vein grafts is not justified.
However, I hope this is not misconstrued to infer that it is
of no benefit in other more difficult distal bypass grafts. In
closing, I would ask the authors if they agree with this or if
they have abandoned Dextran 40 in their practice entirely.
Dr. Steven G. Katz. Dr. Rutherford, I thank you for
your comments. I believe that we are in agreement as to the
use of dextran in patients undergoing infrainguinal bypass
graft surgery. Although we have abandoned the use of dex-
tran in patients undergoing autogenous reconstructions, we
continue to use it routinely in patients undergoing prosthet-
ic bypass graft operations.
Dr. William C. Krupski (Denver, Colo.). I have two
statistical concerns about your study. First of all, you ana-
lyzed by procedure. So you are counting patients twice,
and there may be responders and nonresponders to
Dextran 40. On one procedure, the patient may have got-
ten Dextran 40 and on the other procedure, not have got-
ten Dextran 40. How did you deal with that?
The second question I have is a concern that there is a
21-patient difference between the control group and the
experimental group. In a randomized prospective study, it
seems that those numbers should be closer together. I am
concerned that you did not analyze this by intent to treat.
Dr. Katz. Those are excellent questions, Dr. Krupski.
We did randomize with intent to treat. The only exclu-
sions from randomization were patients in whom dextran
administration would be hazardous, and these exclusions
were made before the randomization process was begun.
Because we did not block randomize, our patient groups
would not be expected to be equal, and my statistician
assures me that these results are well within the expected
parameters.
We considered the question of whether to include
patients undergoing bilateral reconstructions in our series.
Because these operations were performed, for the most
part, on opposite extremities often months to years apart
with different conduits, we believed that they behaved as
independent rather than dependent variables and thus
included them in our study groups.
Dr. Roy Tawes (Burlingame, Calif.). When you started
your lecture, you mentioned hypercoagulable states. I
noticed in your age distribution that there were many
young patients, and indeed Drs. Flanigan and Donaldson
demonstrated that people in their 40’s and early 50’s who
undergo infrainguinal bypass grafts do have a higher inci-
dence rate of hypercoagulable states.
I would like to ask two questions. Focusing on your
failures, they were equal in both your control and Dextran
40 group. Were there any hypercoagulable patients? I
intuitively would expect Dextran 40 to be of more benefit
in these patients than patients failing mainly just because
of poor outflow. Did they all have poor outflow?
As for my second question, I think there are enough data
in the literature that indicate that Dextran 40, used selec-
tively as Dr. Rutherford indicated in these difficult cases, is
inferior to heparin with conversion to Coumadin long term
in hypercoagulable states. Would you comment on that?
Dr. Katz. We only had a few patients who were in the
younger category. The age range was broad, but the aver-
age age was about 72 years. We did not specifically identi-
fy patients with a hypercoagulable state. As to commenting
on whether switching from heparin therapy to Coumadin
is more beneficial in high-risk patients than Dextran 40
conversion to Coumadin, I cannot answer that question.
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